Adynxx Receives NIH HEAL Initiative Funding Award for Development of Second Non-Opioid Pain Therapeutic SAN FRANCISCO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...

Hemispherx Biopharma Reviews Ampligen® Data With National Institute of Neurological Disorders and Stroke (NINDS) PHILADELPHIA, March 10, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced that the strong commitment by the National Institutes of Health (NIH)...